Changes in IL-5 levels and other immunosuppressive or antitumor cytokines have been observed by other groups, highlighting a solid correlation between patient progression (and consequently, an increase in tumor burden both at the skin and blood levels) and an increase in immunosuppressive cytokine profile, including IL-5 [137]. This evidence concerns the gene IL5 and neoplasm.